Filing Flows › Caris Life Sciences (CAI) › Q4 2025
Caris Life Sciences (CAI) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 3, 2026
Caris Life Sciences (CAI) reported revenue of $293M for the fourth quarter 2025 (Q4 2025), +125% from a year earlier and +35% from the quarter before. Operating margin was 30.2%, net earnings $82.0M (28.0% of revenue).
Caris Life Sciences, Q4 2025: revenue $293M (+125% year over year), operating margin 30.2%, net earnings $82.0M, operating cash flow $44.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $293M | +35% | +125% |
| Operating profit | $88.4M | +171% | — |
| Net earnings | $82.0M | +237% | — |
| Operating cash flow | $44.8M | -28% | — |
| Free cash flow | $39.7M | — | — |
What changed
Revenue was $292.9M in Q4 2025, up 125% year over year and up 35% from the previous quarter. Molecular Profiling Services was the largest line at 96% of revenue.
Operating profit was $88.4M, a 30.2% margin (up 58.7 points year over year). Total costs grew 22% against revenue growth of 125%. The fastest-growing cost line was General & admin (+31%). Net earnings were $82.0M. The effective tax rate was 0.0%.
Operating cash flow was $44.8M, 55% of net earnings. Non-cash charges added back $4.3M of depreciation and amortization and $13.4M of share-based compensation. Working capital and other items used $54.8M. After purchases of property and equipment ($5.1M), free cash flow as the company reports it was $39.7M.
Questions
What was Caris Life Sciences' revenue in the fourth quarter 2025?
Caris Life Sciences (CAI) reported revenue of $293M for the fourth quarter 2025 (Q4 2025), +125% from a year earlier and +35% from the quarter before.
Was Caris Life Sciences profitable in the fourth quarter 2025?
Operating profit was $88.4M (30.2% of revenue) and net earnings $82.0M.